The use of buserelin-depo in the treatment of endometriosis

The article presents the current data on the pathogenetic validity of the use of gonadotropin-releasing hormone (GnRH) agonists in the therapy of severe forms of endometriosis. Endometriosis is a multifactorial, hormone-dependent disease that is common in women of reproductive age and results in a significant reduction in quality of life and impaired reproductive function. In most cases, the treatment of endometriosis requires a comprehensive approach, including not only surgical treatment but also postoperative adjuvant hormonal therapy to reduce the recurrence rate. The analysis of the literature demonstrated the efficacy of the Russian drug Buserelin-depo in the management of pain, the treatment of abnormal uterine bleeding, the reduction of uterine size in adenomyosis, as well as in the preparation of patients with endometriosis for surgical treatment and in postoperative adjuvant therapy. The postoperative cyclic administration of Buserelin-depo effectively reduces the recurrence rate of endometriosis, normalises the volume of menstrual blood loss and reduces the risk of repeated ovarian surgery.

Conclusion: The treatment of endometriosis with hormonal therapy is a complex process that requires an individualised approach, taking into account the patient’s age, reproductive plans and somatic status. The combination of surgical treatment with GnRH agonists has been demonstrated to provide rapid relief of clinical symptoms, restoration of quality of life, reduction in the risk of pathology recurrence, and improvement in reproductive outcomes. The use of GnRH agonists promotes organ-preserving surgeries, reducing the risk of postoperative complications and recurrences.